Otsuka Holdings Co., Ltd.
Otsuka Holdings Co., Ltd.
Your view on OTSKY
Overview
What the company does, where it operates, and who runs it.
About Otsuka Holdings Co., Ltd.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Makoto Inoue
- Headquarters
- 2-9 Kanda-Tsukasamachi, Tokyo, JP
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Makoto Inoue
- Headquarters
- 2-9 Kanda-Tsukasamachi, Tokyo, JP
Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses.
It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine.
In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes.
Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Otsuka Holdings Co., Ltd., and the rating behind it. OTSKY last traded at $33.58, 14.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Otsuka Holdings Co., Ltd.. Starting points for Otsuka Holdings Co., Ltd.: P/E 14.8, EPS $384.89, beta -0.13 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Otsuka Holdings Co., Ltd.. Otsuka Holdings Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Otsuka Holdings Co., Ltd.. Trailing twelve-month EPS for Otsuka Holdings Co., Ltd. stands at $384.89. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Otsuka Holdings Co., Ltd.. Otsuka Holdings Co., Ltd. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Otsuka Holdings Co., Ltd. valued side by side against its closest peers. Otsuka Holdings Co., Ltd. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Otsuka Holdings Co., Ltd., and how their positions are changing. At a $36.61B market value, institutional positions materially move Otsuka Holdings Co., Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Otsuka Holdings Co., Ltd. executives and directors. Shares of Otsuka Holdings Co., Ltd. have traded between $21.64 and $34.93 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Otsuka Holdings Co., Ltd.. Otsuka Holdings Co., Ltd. is a $36.61B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Otsuka Holdings Co., Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Otsuka Holdings Co., Ltd.. Coverage tracks Otsuka Holdings Co., Ltd. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.